Anti-malaria drug trial on Covid-19 patients suspended by WHO due to safety reasons

0
636
70% of Infections Can Be Prevented With Good Hand Hygiene And Other Practices : WHO
70% of Infections Can Be Prevented With Good Hand Hygiene And Other Practices : WHO

New Delhi: May 26: Taking a major step, World Health Organization has suspended testing the malaria drug hydroxychloroquine in Covid-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.

Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The US President has said he was taking the drug to help prevent infection.

“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.

He said the other arms of the trial – a major international initiative to hold clinical tests of potential treatments for the virus – were continuing.

WHO has earlier recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.

Dr. Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”.

Source: GNS

Also Read  Bhupesh Baghel sworn in as Chhattisgarh's 3rd CM

LEAVE A REPLY

Please enter your comment!
Please enter your name here